Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:6:801-6.
doi: 10.2147/OPTH.S31859. Epub 2012 May 28.

Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy

Fabio Mazzolani  1
Affiliations

Pilot study of oral administration of a curcumin-phospholipid formulation for treatment of central serous chorioretinopathy

Fabio Mazzolani. Clin Ophthalmol. 2012.

Abstract

Background: The purpose of this open-label study was to investigate the effect of a curcumin-phospholipid (lecithin, Meriva(®)) formulation (Norflo(®) tablet) on visual acuity and retinal thickness in patients with acute or chronic central serous chorioretinopathy.

Methods: Visual acuity was assessed by ophthalmologic evaluation, and optical coherence tomography was used to measure retinal thickness. Norflo tablets were administered twice a day to patients affected by central serous chorioretinopathy. The study included 18 eyes from 12 patients who completed a 6-month follow-up period. Visual acuity before and after Norflo treatment was the primary endpoint. The secondary endpoints were neuroretinal or pigment epithelial detachment, as measured by optical coherence tomography.

Results: After 6 months of therapy, 0% of eyes showed reduction in visual acuity, 39% showed stabilization, and 61% showed improvement. The improvement was statistically significant (P = 0.08). After 6 months of therapy, 78% of eyes showed reduction of neuroretinal or retinal pigment epithelium detachment, 11% showed stabilization, and 11% showed an increase.

Conclusion: Our results, albeit preliminary, show that curcumin administered as Norflo tablets is efficacious for the management of central serous chorioretinopathy, a relapsing eye disease, and suggest that bioavailable curcumin is worth considering as a therapeutic agent for the management of inflammatory and degenerative eye conditions, including those that activate the retinal microglia.

Keywords: Meriva®; Norflo®; central serous chorioretinopathy; curcumin; retinal pigment epithelium detachment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Visual acuity after 6 months of treatment with the curcumin-lecithin formulation.
Figure 2
Figure 2
Retinal thickness after 6 months of treatment with the curcumin-lecithin formulation. Abbreviation: OCT, optical coherence tomography.
Figure 3
Figure 3
Retinal thickness after 6 months of treatment with the curcumin-lecithin formulation in three different cases. (A) Case 1, reduction of a subfoveal neuroretinal detachment. (B) Case 2, reduction of a juxtafoveal retinal pigment epithelium detachment and extrafoveal neuroretinal detachment. (C) Case 3, reduction of a juxtafoveal retinal pigment epithelium and extrafoveal neuroretinal detachment.
See this image and copyright information in PMC

References

    1. Graefe AV. Uber centrale recidivierende retinitis. Graefes Arch Clin Exp Ophthalmol. 1866;12:211–215. [German]
    1. Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol. 1967;63(Suppl 3):1–139. - PubMed
    1. Mohan R, Sivak J, Ashton P, et al. Curcuminoids inhibit the angiogenic response stimulated by fibroblast growth factor-2, including expression of matrix metalloproteinase gelatinase B. J Biol Chem. 2000;275(14):10405–10412. - PubMed
    1. Chen M, Hu DN, Pan Z, Lu CW, Xue CY, Aass I. Curcumin protects against hyperosmoticity-induced IL-1 beta elevation in human corneal epithelial cell via MAPK pathways. Exp Eye Res. 2010;90(3):437–443. - PubMed
    1. Bengmark S. Curcumin, an atoxic antioxidant and natural NF kappaB, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. JPEN J Parenter Enteral Nutr. 2006;30(1):45–51. - PubMed